Biotechnology at University of Illinois Urbana-Champaign

A debt-to-earnings ratio of 0.43—based on what similar biotechnology bachelor's programs produce nationally—puts this program in reasonable territory, though not spectacular. With an estimated $20,400 in debt against projected first-year earnings around $47,000, graduates would be looking at manageable repayment if those estimates hold. The challenge here is that we're working entirely from national peer data since Illinois has only three biotech programs and none have sufficient graduate samples for the DOE to publish outcomes.

What you're buying is less about biotech-specific outcomes data and more about the broader Illinois credential. The university's 1418 SAT average and 44% admission rate suggest a competitive undergraduate environment, which matters for the networking and research opportunities that often separate biotech graduates who land strong industry positions from those who struggle. Biotechnology at the bachelor's level can be a tricky field—it's specialized enough to signal STEM capability but not always specialized enough to command premium starting salaries without additional credentials.

The estimated earnings align exactly with the national median, suggesting neither advantage nor disadvantage compared to peer programs. For parents, the key question is whether your student plans to stop at the bachelor's or continue to graduate school, where many biotech careers truly begin. If this is a stepping stone to a PhD or master's, the moderate debt load is workable. If it's a terminal degree, your student should pursue internships aggressively to ensure they're positioned for the better outcomes within that $47,000-$52,000 range where most programs cluster.